Clinical trial
A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in…
NCT00370383 · Agennix, Industry · Completed
Key facts
| NCT number | NCT00370383 |
|---|---|
| Title | A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC) |
| Official title | A Phase 2 Study Comparing Sequential Satraplatin and Erlotinib to Single-Agent Erlotinib in Patients ≥ 70 Years of Age With Unresectable Stage 3 OR 4 Non-Small Cell Lung Cancer as 1st-Line Therapy |
| Lead sponsor | Agennix, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib, Satraplatin |
| Enrollment | 100 |
| Start date | Jul 1, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Aug 31, 2006 |
| Last update posted | Aug 7, 2012 |
| Countries | Canada, Chile, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: